SynthesisEuropean radiology2025
Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis.
Synthesis in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic performance of ultrasound attenuation imaging in detecting hepatic steatosis.Journal of medical ultrasonics (2001) · 2026Pooled it
- Assessment of the Diagnostic Performance and Clinical Impact of AI in Hepatic Steatosis: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- The diagnostic value of MRI-PDFF in hepatic steatosis of patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Hepatic steatosis in humans is associated with preserved glucagon action on amino acid metabolism.The Journal of clinical investigation · 2026Trial
- Effect of high-intensity interval training in patients with chronic hepatitis B and hepatic steatosis: A randomised controlled trial.PloS one · 2026Trial
- Review
- Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Quantitative Multifrequency Ultrasound Imaging Using Narrowband Pulsing for Tissue Characterization.Investigative radiology · 2026Article
- MRI in MASLD: technical foundations and guideline-based applications.BMJ open gastroenterology · 2026Review
- [Research progress on the applicability of diagnostic criteria for metabolic and alcohol-related liver disease in patients with cirrhosis and after liver transplantation].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Liver findings in newly diagnosed, treatment-naive patients with Crohn's disease: a preliminary study of MRI proton density fat fraction and extracellular volume fraction.BMC medical imaging · 2026Article
- Correlative study of hepatic venous diameter/liver volume index and extent of hepatic steatosis in living related liver donors: a retrospective observational study.Clinical transplantation and research · 2026Article
- Diagnostic Performance of Ultrasound-Guided Attenuation Parameter (UGAP) for Hepatic Steatosis Assessment: Comparison with MRI-PDFF and Evaluation of Cohort-Derived Thresholds.Diagnostics (Basel, Switzerland) · 2026Article
- MRI-proton density fat fraction accurately reflects hepatic steatosis despite concomitant inflammation and fibrosis in a MASLD rat model.Abdominal radiology (New York) · 2026Article
- Liver CT-based composite biomarkers can identify MASH and steatosis grade in people with obesity prior to bariatric surgery: a retrospective study.BMC gastroenterology · 2026Article
- Fraction Conversion Models Based on Ultrasound Attenuation Coefficient for Assessing Liver Steatosis.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnostic Value of MR Elastography and MRI-Proton Density Fat Fraction in Cirrhosis Based on Explant Liver Histology.Journal of gastroenterology and hepatology · 2026Article
- AI-powered ultrasound radiofrequency analysis for non-invasive pediatric liver fat quantification.Scientific reports · 2026Article
- Comparison of Manual Multi-ROI, Single-Location, and Volumetric Fat Fraction Measurements for Hepatic Steatosis Using MRI.Diagnostics (Basel, Switzerland) · 2026Article
- New Treatment Options for MASLD Patients with Type 2 Diabetes.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmidst the global rise of metabolic dysfunction-associated steatotic liver disease (MASLD), driven by increasing obesity rates, there is a pressing need for precise, non-invasive diagnostic tools. Our research aims to validate MRI Proton Density Fat Fraction (MRI-PDFF) utility, compared to liver biopsy, in grading hepatic steatosis in MASLD.
methodsA systematic search was conducted across Embase, PubMed/Medline, Scopus, and Web of Science until January 13, 2024, selecting studies that compare MRI-PDFF with liver biopsy for hepatic steatosis grading, defined as grades 0 (< 5% steatosis), 1 (5-33% steatosis), 2 (34-66% steatosis), and 3 (> 66% steatosis).
resultsTwenty-two studies with 2844 patients were included. The analysis showed high accuracy of MRI-PDFF with AUCs of 0.97 (95% CI = 0.96-0.98) for grade 0 vs ≥ 1, 0.91 (95% CI = 0.88-0.93) for ≤ 1 vs ≥ 2, and 0.91 (95% CI = 0.88-0.93) for ≤ 2 vs 3, diagnostic odds ratio (DOR) from 98.74 (95% CI = 58.61-166.33) to 23.36 (95% CI = 13.76-39.68), sensitivity and specificity from 0.93 (95% CI = 0.88-0.96) to 0.76 (95% CI = 0.63-0.85) and 0.93 (95% CI = 0.88-0.96) to 0.89 (95% CI = 0.84-0.93), respectively. Likelihood ratio (LR) + ranged from 13.3 (95% CI = 7.4-24.0) to 7.2 (95% CI = 4.9-10.5), and LR - from 0.08 (95% CI = 0.05-0.13) to 0.27 (95% CI = 0.17-0.42). The proposed MRI-PDFF threshold of 5.7% for liver fat content emerges as a potential cut-off for the discrimination between grade 0 vs ≥ 1 (p = 0.075).
conclusionMRI-PDFF is a precise non-invasive technique for diagnosing and grading hepatic steatosis, warranting further studies to establish its diagnostic thresholds. CLINICAL RELEVANCE STATEMENT: This study underscores the high diagnostic accuracy of MRI-PDFF for distinguishing between various grades of hepatic steatosis for early detection and management of MASLD, though further research is necessary for broader application. KEY POINTS: MRI-PDFF offers precision in diagnosing and monitoring hepatic steatosis. The diagnostic accuracy of MRI-PDFF decreases as the grade of hepatic steatosis advances. A 5.7% MRI-PDFF threshold differentiates steatotic from non-steatotic livers.
Indexed as
Identifiers
39254718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.